PKM2 inhibitor (compound 3k) is primarily studied for its potential in cancer therapy. By targeting pyruvate kinase M2 (PKM2), a key enzyme in cancer cell metabolism, it disrupts the glycolytic pathway essential for the proliferation of cancer cells. This inhibition can lead to reduced tumor growth and increased sensitivity to other cancer treatments. Additionally, it is being explored for its role in modulating immune responses in the tumor microenvironment, potentially enhancing the efficacy of immunotherapies. Research is ongoing to evaluate its therapeutic potential in various cancer types and its ability to improve patient outcomes.